The Houston, TX-based company is developing the Aortix system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function.
The investment will fund the company’s pilot study through the activities needed to support the submission of an FDA IDE application for its pivotal trial. To date, the firm said it has raised more than $59 million in funding.
